Osimertinib Treats CNS Metastases in NSCLC
- PMID: 30224350
- DOI: 10.1158/2159-8290.CD-NB2018-121
Osimertinib Treats CNS Metastases in NSCLC
Abstract
The EGFR inhibitor osimertinib may be an effective therapy for patients with untreated non-small cell lung cancer who have brain metastases. In a recent study, the drug extended median progression-free survival and increased objective response rates compared with the first-generation EGFR inhibitors gefitinib and erlotinib.
©2018 American Association for Cancer Research.
Comment on
-
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.J Clin Oncol. 2018 Aug 28:JCO2018783118. doi: 10.1200/JCO.2018.78.3118. Online ahead of print. J Clin Oncol. 2018. PMID: 30153097
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
